Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EPS (Weighted Average and Diluted) (2020 - 2025)

Foghorn Therapeutics has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.34 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.34 for Q4 2025, down 13.33% from a year ago — trailing twelve months through Dec 2025 was -$1.17 (up 29.09% YoY), and the annual figure for FY2025 was -$1.18, up 25.32%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.34 at Foghorn Therapeutics, down from -$0.25 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for FHTX hit a ceiling of -$0.25 in Q3 2025 and a floor of -$0.77 in Q4 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.6 (2021), compared with a mean of -$0.53.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 78.28% in 2021, while the deepest fall reached 130.43% in 2021.
  • Foghorn Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.77 in 2021, then increased by 10.39% to -$0.69 in 2022, then rose by 17.39% to -$0.57 in 2023, then skyrocketed by 47.37% to -$0.3 in 2024, then dropped by 13.33% to -$0.34 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.34 (Q4 2025), -$0.25 (Q3 2025), and -$0.28 (Q2 2025) per Business Quant data.